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Abstract
Background: Preterm birth (PTB) remains the leading cause of neonatal mortality and long term disability
throughout the world. Though complex in its origins, a growing body of evidence suggests that first trimester
administration of low dose aspirin (LDA) may substantially reduce the rate of PTB.
Methods: Hypothesis: LDA initiated in the first trimester reduces the risk of preterm birth.
Study Design Type: Prospective randomized, placebo-controlled, double-blinded multi-national clinical trial
conducted in seven low and middle income countries. Trial will be individually randomized with one-to-one ratio
(intervention/control)
Population: Nulliparous women between the ages of 14 and 40, with a singleton pregnancy between 6 0/7 weeks
and 13 6/7 weeks gestational age (GA) confirmed by ultrasound prior to enrollment, no more than two previous
first trimester pregnancy losses, and no contraindications to aspirin.
Intervention: Daily administration of low dose (81 mg) aspirin, initiated between 6 0/7 weeks and 13 6/7 weeks GA
and continued to 36 0/7 weeks GA, compared to an identical appearing placebo. Compliance and outcomes will
be assessed biweekly.
Outcomes: Primary outcome: Incidence of PTB (birth prior to 37 0/7 weeks GA).
Secondary outcomes Incidence of preeclampsia/eclampsia, small for gestational age and perinatal mortality.
Discussion: This study is unique as it will examine the impact of LDA early in pregnancy in low-middle income
countries with preterm birth as a primary outcome. The importance of developing low-cost, high impact
interventions in low-middle income countries is magnified as they are often unable to bear the financial costs of
treating illness.
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Background
Preterm delivery, defined as delivery prior to 37 weeks 0/
7 days gestation, remains the dominant cause of neonatal
morbidity and mortality throughout the world [1–3] and
directly leads to 28% of neonatal deaths within the first
seven days of life [4]. Moreover it is responsible for up to
50% of pediatric neurodevelopmental disorders [5]. Infants
born prematurely are also at increased risk for long term
medical complications such as respiratory, gastrointes-
tinal, cardiovascular, metabolic, and neurodevelopmental
disorders [6, 7].
The risk of preterm birth is highest in low-middle in-
come countries where an estimated 12% of births are
preterm compared to 5-7% in high-income countries [8].
Of the near 13 million preterm births worldwide in
2005, 11 million were in Africa and Asia [9]. Given the
tremendous medical, financial and emotional burden of
preterm birth in the developing world and the limited
resources to provide neonatal care, any interventions
with the potential to reduce the rate of preterm birth de-
serve consideration. An ideal intervention to reduce pre-
term birth would be one that is widely available,
inexpensive, and safe for the mother and fetus. Low dose
aspirin (LDA) may be just such an intervention.[6, 7]
Biology of aspirin in pregnancy
Aspirin is best known for its analgesic properties; however,
it is well documented that aspirin is an anti-inflammatory
and potent inhibitor of platelet aggregation, contributing to
its anti-thrombotic effects. Both inflammation and throm-
bosis are implicated in pathways responsible for many cases
of preterm birth, preeclampsia and fetal growth restriction.
The primary biologic effects of aspirin are mediated by in-
hibition of the enzyme cyclooxygenase (Cox) [10–12], which
produces substances known to be involved in the defined
pathways of spontaneous preterm birth and placental dys-
function (preeclampsia/growth restriction/stillbirth) [13]. By
decreasing these mediators and in turn decreasing inflam-
mation and placental dysfunction due to thrombosis, aspirin
may reduce the rates of the major obstetrical complications
of preterm birth, preeclampsia and growth restriction.
The time frame in which LDA is initiated appears to be
important. Biologically it has been demonstrated that the
process of preterm birth in many cases begins prior to
16 weeks [13]. Likewise, placental invasion of the maternal
decidua occurs in the first trimester and underlies the
pathologic processes of preeclampsia and pathologic
growth restriction. Thus, aspirin may be maximally effect-
ive if initiated in the first trimester. Indeed, this is supported
by available data (see below).
Aspirin and preterm birth
Though available evidence is promising, data regarding
the early use of low-dose aspirin (LDA) in pregnancy to
prevent preterm birth are limited. A single trial of pre-
conception aspirin and meta- analyses that examine the
subset of women in larger studies that have begun LDA
16 weeks or earlier, have shown a persistent impact on
preterm birth. For example, Roberge et al., in a meta-
analysis of LDA included 22 trials that included 11,302
women, found a 19% reduction in the overall rate of pre-
term birth (RR 0.81, 95% CI 0.71 to 0.92) [14]. However
when the analysis was restricted to women who initiated
aspirin prior to 16 0/7 weeks, a 65% reduction was ob-
served (6 trials including 904 women, RR 0.35, 95% CI
to 0.22 to 0.57).
A trial of preconception LDA, the Effects of Aspirin in
Gestation and Reproduction (EAGeR) trial shows a simi-
lar trend towards risk reduction in a cohort of 1,078
women who were randomized to LDA prior to concep-
tion. If only the original cohort (women with just one
prior loss or less) is examined, there is a 55% reduction
in preterm birth (RR 0.45; p-value of 0.087; CI 0.19 to
1.08). When expanded to include the entire cohort (in-
cludes women with more than one fetal loss), there is a
28% risk reduction (RR of 0.72; p value 0.260). The lack
of significant difference in this trial is not surprising
given the small number of women with PTB but the
trend is encouraging [15], a reduction in the rate of PTB
between 28% and 65%.
Aspirin and preeclampsia
Many large randomized controlled clinical trials have ex-
amined the efficacy of LDA in preventing preeclampsia.
Duley and colleagues performed a systematic review that
included 51 trials involving 36,500 women treated with
antiplatelet agents for the prevention of preeclampsia
[16]. Forty-four of these trials involved the use of aspirin
alone (compared with placebo or no treatment) while
the remainder included other treatments, often in con-
junction with aspirin. Overall, the use of antiplatelet
agents conferred a 19% reduction in the risk of pre-
eclampsia (RR 0.81; 95% CI, 0.74-0.96). There was a
greater risk reduction in women treated with doses
greater than 75 mg/day (RR 0.49, 95% CI 0.38-0.65)
compared to lower doses (RR 0.86, 95% CI 0.79-0.93).
Other reviews emphasize the increased benefit from
LDA in women with historical risk factors (high risk for
preeclampsia) and suggest that focusing on at risk
groups would decrease the number of women it is ne-
cessary to treat to prevent a single case of preeclampsia
[17–19]. As with preterm birth, the effect size increases
when LDA is initiated earlier in gestation. A meta-
analysis of 33 trials reported a risk reduction of 0.62
(95% CI 0.49 to 0.78); however, when this was restricted
to women who began therapy <16 weeks the effect size
was greater (RR 0.47, 95% CI 0.36 to 0.62). Of course,
the “risk: benefit” ratio also is influenced by risk, which
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appears to be quite low for LDA. Thus, treatment of low
risk women may be justified.
Aspirin and growth restriction (small for gestational Age)
Low dose aspirin also may reduce the risk of other ad-
verse perinatal outcomes such as fetal growth restriction
and late fetal death. In 32 trials of 24,310 women, anti-
platelet therapy conferred an 8% reduction in SGA (RR
0.92, 95% CI 0.85-1.00) in women treated with the intent
to prevent preeclampsia [20]. LDA also has not been ef-
fective when started after the diagnosis of preeclampsia
or diagnosis of a growth restricted fetus [21–23]. Once
again, early initiation may be the key to success. A meta-
analysis reported a 14% reduction in fetal growth restric-
tion among women treated with LDA (RR 0.86, 95% CI
0.75-99); however when only women who initiated ther-
apy at or before 16 weeks were examined the effect size
was 54% (RR 0.46, 95% CI 0.33-0.66) [14].
The review by Duley and colleagues noted a 16% re-
duction in combined fetal, neonatal, and infant mortality
in women taking antiplatelet therapy (RR 0.84, 95% CI
0.74-0.96) [24]. Perinatal death and SGA fetuses were
not primary end points of these trials.
Aspirin safety
LDA is attractive as a potential therapy for reproductive
disorders because it has a demonstrated track record of
both fetal and maternal safety. Randomized controlled
trials (RCTs) in thousands of women showed no in-
crease in adverse fetal sequelae in doses < 150 mg per
day [22, 24]. In a meta-analyses of 22 studies, aspirin
was not associated with an overall increase in the risk
of congenital malformations [25]. The same meta-
analysis reported an increase in the risk of gastroschi-
sis (OR 2.37; 95% CI, 1.44 – 3.88) in infants exposed
to high-dose aspirin (325 mg per day) in the first tri-
mester [25]. This is biologically plausible since this
malformation may be caused by vascular disruption of
mesenteric vessels [26]. Results were not confirmed in
a recent population based case-control study [27, 28]
and the cause and effect between low dose aspirin
use and gastroschisis remains uncertain. Studies re-
garding safety are difficult to compare due to differ-
ent doses, duration, and timing of aspirin use (with
regard to pregnancy). Nonetheless, the majority of
data indicates minimal fetal risk from in utero LDA
exposure. In fact, a recent study noted that LDA was
actually associated with a reduction in neurobehav-
ioral difficulties in very preterm infants [29].
In terms of maternal safety, a metal-analyses of 22,760
women found no difference in the rate of postpartum
hemorrhage amongst women using LDA and placebo
[30]. Similarly the rates of abruption and discontinuation
were similar between LDA and placebo [30].
Summary
We intend to study the effects of LDA in nulliparous
women for several reasons. First, although it would be of
interest to study the effect of LDA in women at high risk
for preterm birth (e.g., prior preterm birth), such women
may undergo interventions intended to decrease their
risk of preterm birth. Thus, a study in patients with
prior preterm birth would have numerous potential con-
founders such as the use of progesterone, cervical cerc-
lage and closer monitoring. Conversely, multiparous
women with prior term births would be at very low risk
for preterm birth and would also be a suboptimal popu-
lation to study. Nulliparous women appear to be an ideal
population since they will not undergo special interven-
tions in an attempt to avoid preterm birth. Also, it ap-
pears that the risk of preterm birth in nulliparous
women is higher than for the general obstetric popula-
tion [31, 32]. In summary, available data suggest that
LDA may be a safe, widely available and inexpensive
intervention that may significantly reduce the risk of
preterm birth. However, this possibility needs to be
proven in a properly designed RCT with preterm birth
as the primary outcome. Such a clinical trial in a racially,
ethnically and geographically diverse population could
best be accomplished through the established infrastruc-
ture of the Global Network for Women’s and Children’s
Health Research (Global Network), a multi-country re-
search network with study sites in India, Pakistan,
Guatemala, Kenya, Zambia and the Democratic Republic
of Congo [33].
Methods/design
Study hypothesis
This trial has the following study hypotheses:
Primary hypothesis or question
Our primary hypothesis is that nulliparous women with no
more than two previous first trimester pregnancy losses
who are treated with LDA daily beginning between 6 0/
7 weeks and 13 6/7 weeks GA through 36 0/7 weeks GA
will reduce the rate of preterm birth from all causes by 20%.
Secondary hypothesis
Women who take antenatal daily LDA initiated at 6 0/7
to 13 6/7 weeks GA will have lower rates of:
 Small for gestational age infants
 Eclampsia and preeclampsia
 Perinatal Mortality
We propose a randomized, placebo-controlled, double-
blinded multicenter clinical trial to assess the efficacy of
LDA in the reduction of preterm birth. Women will be
randomized equally to receive either daily LDA (81 mg) or
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an identical appearing placebo beginning between 6 0/
7 weeks and 13 6/7 weeks GA and continuing until 36 0/
7 weeks GA or delivery.
Study Population
A total of 11,920 nulliparous women will be enrolled
(5960 per group) across seven sites in sub-Saharan Af-
rica, South Asia, and Latin America. For balance, each
site will enroll no more than 25% of the total sample. To
study the possible effect of LDA on anemia, we will
enroll 500 women in a sub-study, with each site contrib-
uting at least 10% of the sample.
Inclusion criteria
Inclusion criteria include the following women who are
residents of the study areas:
 Nulliparous women between 18 – 40 years of age
(Minors who are ≥ 14 years of age may be enrolled if
permitted by the country’s ethical guidelines.);
 No more than two previous first trimester
pregnancy losses;
 No medical contraindications to aspirin;
 Single live intrauterine pregnancy (IUP) between 6
0/7 and 13 6/7 weeks GA corroborated by an early
dating ultrasound and presence of a heartbeat.
Exclusion criteria
The following are the study exclusion criteria:
 Women already prescribed daily aspirin for more
than 7 days;
 Women with multiple gestations;
 Fetal anomaly by ultrasound (Note: most fetal
anomalies are not detectable by ultrasounds done at
this early gestation. Subsequent discovery of a fetal
anomaly is not an exclusion.);
 Hemoglobin < 7.0 g/dl at screening;
 Systolic blood pressure ≥ 140 and diastolic ≥ 90 at
screening;
 Any other medical conditions that may be
considered a contraindication per the judgment of
the site investigator (e.g., Lupus, Type 1 Diabetes,
hypertension, or any other known significant
disease).
Study procedures
The schedule of study procedures is outlined in Table 1.
Initial screening
Potential study participants will be recruited using mul-
tiple strategies so as to reach a diverse study population
that includes nulliparous women who are pregnant. To
reach the maximum number of potential participants,
clinic-based and community-based recruitment methods
will be used. Sites will determine the most effective
method for their hospital/community.
Upon identification, a brief assessment of eligibility
will be made to determine whether the patient is nul-
liparous and pregnant in the required GA window based
on last menstrual period (LMP), has no more than two
previous 1st trimester pregnancy losses, and has no med-
ical contraindications to aspirin or pregnancy. Know-
ledge of exact LMP and/or GA are not absolute
contraindications to study enrollment, as ultrasound will
ultimately determine the participant’s GA.
The initial screening will include collection of infor-
mation on specific medical conditions, prior surgical
procedures, medication use, allergy history, and out-
comes of any prior pregnancies. If a contraindication to
participation in the trial is found, the woman will be ex-
cluded from the trial at this point. If the field staff are
uncertain about whether a woman is an appropriate can-
didate, her enrollment will be deferred until study inves-
tigators can review her medical history. Women who
meet medical history eligibility criteria will proceed to
have an ultrasound performed.
Ultrasound screening
To be included in the study, the following three findings
must be obtained via ultrasound:
 A single intrauterine gestation
 Presence of a fetal heart rate
 Crown rump length (CRL) < 14 weeks gestation
Ultrasound will be assessed in all participants consist-
ent with local good clinical practice. To obtain the CRL,
a total of 3 measurements should be obtained in milli-
meters and the average should be utilized. Other mea-
surements, such as the size of the gestational sac, will
not be used. All study sonographers will be trained to
assess gestational age using CRL measurements and
quality will be monitored.
Since accurate information about LMP is frequently be
unavailable in our prospective study population, gesta-
tional age will be assigned solely with the use of ultra-
sound measurement of CRL. The assignment of the
projected due date will be consistent with the recent dir-
ection provided by the NICHD consensus statement
[34] shown in Table 2.
Clinical assessment
Each participant will be assessed to determine clinical
status. The assessment will consist of a brief physical
examination, medical history, and questions about the
use of other medicines or medicinal products. It will also
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include a baseline hemoglobin (Hb) measurement. If the
Hb measurement is < 7.0 g/dl, she will be excluded from
the study.
Randomization procedures
Randomization of subjects will be carried out to obtain a
1:1 allocation ratio between the treatment and placebo
arms. Randomization will be stratified by site. A com-
puter algorithm generated by the data coordinating cen-
ter (DCC) will create the random assignment to one of
the treatment arms based on randomly permuted block
design with randomly varied block sizes, known only by
the DCC personnel.
Table 2 Guidelines for assigning projected due date
Gestational age by LMP Difference between
LMP and US GA
Basis for assigning
projected due date
Unknown/Not available N/A CRL
<9 0/7 weeks >5 days CRL
≤5 days LMP
≥9 0/7 and ≤13 6/7 weeks >7 days CRL
≤7 days LMP
Table 1 Timing of procedures
6 0/7- 13 6/
7 weeks GA
Bi-weekly
after enrollment
4 weeks
after enrollment
16-20
weeks
GA
26-30
weeks
GA
28-30
weeks
GA
34 weeks
GA
36 weeks
GA until
delivery
6 weeks
Post-Partum
As
needed
Screening
Initial eligibility ●
Ultrasound ●
Consent ●
Randomization/Enrollment ●
Clinical Assessments
Physical exam ●
Medical history ●
Use of other medicines ● ●
Maternal Hb monitoring ● ● ●
BP Monitoring ● ● ● ● ●
Medication Activities
Instructions for
medication use
● ●
Medication compliancea ●
Resupply ●
Outcome Assessment
Preterm Birth ●
SGA ●
Preeclampsia/Eclampsia ● ● ● ● ● ● ●
Other maternal outcomes ● ● ●
Other fetal outcomes ● ●
Unanticipated medical care ● ●
Serious Adverse Events ● ● ●
aMedication is supplied until 36 weeks GA; therefore duration of medication-related monitoring depends on GA at randomization
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Study intervention and comparison
The study intervention is 81 mg of aspirin administered
daily beginning between 6 0/7 weeks and 13 6/7 weeks
through 36 0/7 weeks or delivery. Though 81 mg and
75 mg doses are both used as standard “low” doses in
developing countries; the 81 mg dose was selected be-
cause it is consistent with the dosage used in other large
trials such as EAGER, is the standard in five of the seven
participating sites, and introduces no additional risk over
the 75 mg dose. In fact, Duley et als meta-analysis
showed a greater risk reduction for the development of
preeclampsia associated with proteinuria in women
treated with doses greater than 75 mg/day (RR 0.49, 95%
CI 0.38-0.65) compared to lower doses (RR 0.86, 95% CI
0.79-0.93).23
Following randomization, each woman will be pro-
vided with a supply of either LDA or an identical
appearing placebo. The drug or placebo will be enteric
coated pills, provided in identical, child-resistant pack-
aging, with written instructions for use. To ensure that
literacy levels will not affect proper use, the study staff
will provide verbal instructions at randomization and
reinforce these guidelines at subsequent follow-up visits.
Each woman will also receive a back-up supply of medi-
cation or placebo, which will be maintained throughout
the duration of the study. The purpose of the backup is
to bridge circumstances wherein the woman misses or is
late to a planned follow-up visit or the primary supply of
study drug/placebo is misplaced or destroyed. Medica-
tion compliance will be monitored through pill counts
and the drug/placebo supply will be replenished during
routine study visits.
Blinding/masking
Both the aspirin and placebo will be procured from the
same manufacturer. Packaging will be standardized
across sites and will be labeled as ASA 81 mg/placebo,
with the expiration data and a unique identifier.
Throughout the study, research staff and local health pro-
viders will be blinded to treatment status unless there is a
serious adverse event potentially related to the treatment
modality that requires un-blinding for safety reasons. One
pharmacist at each site will remain unmasked to monitor
randomization, drug supply, and safety as needed.
Monitoring
Participants will meet with study staff biweekly to
monitor medical side effects and other medical co-
interventions. As this is a pragmatic trial, no limitations
on local treatment will be prescribed but rather simply
documented. An assessment of unplanned medical visits
will also be made at this time. Routine study visits will
also provide an opportunity to monitor drug compliance
and exchange her completed drug/placebo supply for a
new allotment of medication. This process will be com-
pleted until the beginning of 36 0/7 weeks GA or the
participant delivers.
In order to assess the development of preeclampsia,
blood pressure will be monitored at the following
time points:
 Between 16 and 20 weeks
 At 28–30 weeks
 At 34 weeks
 Every 2 weeks beyond that until delivery, alternating
with pill monitoring visits
Each visit will consist of routine blood pressure mea-
surements using a standardized blood pressure instru-
ment and protocol. If the blood pressure is found to be
>140/90, then proteinuria will be evaluated by urine dip-
stick, and the participant will be referred, as indicated.
Primary outcome
The primary outcome of this study is preterm birth,
which will be defined as delivery at or after 20 0/7 weeks
and prior to 37 0/7 weeks. This will be determined based
on actual date of delivery in comparison to the projected
EDD, independent of whether or not the preterm deliv-
ery is indicated or spontaneous.
Secondary outcomes
 Preeclampsia and eclampsia
 SGA newborn
 Perinatal mortality
Other outcomes of interest
Maternal outcomes:
 Vaginal bleeding
 Antepartum hemorrhage
 Postpartum hemorrhage
 Maternal mortality
 Late pregnancy termination
 Change in maternal hemoglobin
Fetal and Neonatal outcomes:
 Preterm birth <34 0/7 weeks of pregnancy
 Birth weight <2500 g and <1500 g
 Fetal loss
 Spontaneous abortion
 Stillbirth
 Medical termination of pregnancy
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Safety monitoring
Aspirin remains the oldest prescribed drug in human
medicine. As such, the safety profile has been well
described. Large longitudinal studies of both adult popu-
lations and pregnant populations have been performed,
with minimal or no side effects detected with the use of
low doses. A 2014 systematic review of the use of LDA
for the prevention of morbidity and mortality from pre-
eclampsia found a 10% reduction in risk of preeclampsia,
20% reduction of SGA and a 14% reduction of preterm
birth [35]. Further, there was no evidence of serious
harms associated with LDA use during pregnancy.
Bleeding-related complications, such as postpartum
hemorrhage, maternal blood loss, and neonatal intracra-
nial or intraventricular bleeding were not increased. The
evidence on longer-term outcomes for offspring from in
utero aspirin exposure (low-dose) is limited, but follow-
up data from one large RCT is reassuring [35]. Nonethe-
less, it should be noted these studies have not assessed
the safety of aspirin in pregnancy in the developing
world where unique circumstances such as endemic
anemia may be present. Therefore safety monitoring re-
mains a strong focus of this project and can be divided
into three distinct areas:
1. Active surveillance of maternal side effects and
medical complications associated with aspirin:
Maternal surveillance will be composed of active
assessment of unintended medical visits. Likewise,
where obtained for clinical care, hemoglobin will be
recorded as well as administration of both oral and
intravenous iron. The incidence of postpartum
hemorrhage, antepartum hemorrhage, cesarean
delivery and maternal death due to postpartum
hemorrhage will also be monitored on an ongoing
basis.
2. Evaluation of fetal side effects: If occurrences of
major fetal abnormalities or fetal loss are discovered
during ultrasound procedures or follow-up visits,
they will be noted and the woman will be referred
according to local standard of care. Likewise, still-
birth and late pregnancy loss (delivery between 16
and 20 weeks) will be monitored via established
maternal and newborn health registry that is
conducted within the Global Network infrastructure
at each site. Fetal anomalies and loss will also be
reviewed at least twice a year by the Data Monitoring
Committee (DMC)
3. Evaluation of changes in maternal hemoglobin:
Anemia will be monitored in all women, with
sequential hemoglobin measurements at
randomization and again between 26-30 weeks GA.
Women with hemoglobin < 7.0 g/dl at
randomization will be excluded from the study.
Hemoglobin will also be measured at 4 weeks post-
randomization in the first 500 available women who
agree to participate, with changes in hemoglobin
assessed by treatment group. Recognizing that site-
specific characteristics may affect maternal
hemoglobin, the 500 woman sample will include at
least 50 women from each site. Women with
hemoglobin levels of < 7.0 g/dL or with a change of
more than 3.5 mg when measured post-
randomization will be referred to a health provider
to receive the local standard of care.
Compliance monitoring
The participant will take daily LDA from the time of
randomization until 36 0/7 weeks GA or delivery. Drug
compliance will be routinely monitored throughout this
period through pill counts and the completion of a
medicine compliance form each time the pill supply is
replenished. An interval medical obstetrical history will
also be taken during these scheduled visits. Study staff
will also provide reminders about proper drug adminis-
tration and the importance of compliance during bi-
weekly visits to monitor side effects.
Site preparation
In preparation for study implementation, the sites will
meet with health authorities and conduct community
sensitization activities to ensure that study procedures
are appropriate for the local context and to encourage
commitment and engagement at the facility and com-
munity level. Site preparation activities will focus on:
 Identifying and hiring study staff;
 Developing site-specific procedures for safety
monitoring (blood pressure, anemia) and procuring
the necessary equipment;
 Exploring locally-acceptable methods to monitor
and improve medication compliance;
 Identifying potential implementation challenges and
developing culturally-appropriate solutions;
 Identifying local medicines/treatments that contain
aspirin or have contraindications for its use;
 Educating health workers and community members
on the use of aspirin in pregnancy (including safety
of aspirin use).
Potential risks and benefits to participants
There are several potential direct and indirect benefits of
this trial. In LMIC, including those of the Global Net-
work, the rate of preterm births can be as high as 19%
of all deliveries amounting to an estimated 15 million
preterm births in 2012 [2, 9]. Should this trial be suc-
cessful and the rate of preterm deliveries be dropped by
20%, we could eliminate 3,750,000 of these early births
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per year. Aspirin has also been shown to decrease the
incidence of stillbirth and delivery of SGA infants [21,
23, 24, 36]. In addition to a reduction of preterm birth,
there is clear evidence of maternal benefit. There are
data supporting the use of daily LDA to prevent pre-
eclampsia [24, 37, 38]. This is an important benefit, as
pregnancy induced hypertension (PIH) is a major con-
tributor to maternal mortality [39].
Globally, preterm delivery remains a major health care
financial burden [2, 40].
By reducing the number of preterm deliveries, the trial
also has the potential to decrease need for extended and
recurrent hospital stays that are frequent in this popula-
tion, as well as impacting the cost of care for the long-
lasting neurodevelopmental disorders and chronic health
conditions incurred later on in life [5–7]. Moreover, with
this simple strategy, we could potentially save the lives
of over one million neonates that die due to prematurity
every year [2].
The safety profile of aspirin is well-established and
thoroughly investigated. Women with a known adverse
reaction to acetylsalicylic acid (aspirin) will be excluded
from the trial. This occurs rarely, but an allergic reaction
to the intervention medication remains a small risk.
Fetal concerns are also limited. Most notably, LDA has
actually been shown to improve neurologic outcomes in
preterm infants [29]. In light of such findings, the med-
ical community acknowledges that antepartum exposure
to low dose aspirin incurs only marginal fetal risk. Over-
all, the profound benefits of this intervention greatly
outweigh the minimal risks to both mother and child.
Analytical plan
Statistical analysis plan
Baseline demographic characteristics and key clinical
measures will be compared between women in the two
treatment arms using contingency table approaches for
categorical variables and analysis of variance models and
t-tests for continuous variables. For all of these analyses,
comparisons will be made within each Global Network
site and overall across the sites controlling for site in the
models.
Primary analysis—risk of preterm (<37 weeks) birth
The primary analysis will compare the risk of preterm
birth between the two treatment arms using two com-
plementary approaches. First, the formal test of the pri-
mary hypothesis that the risk of preterm birth differs
between the two arms will utilize a modified intention-
to-treat approach based on a Cochran-Mantel-Haenszel
(CMH) test stratified by Global Network sites. The ap-
proach is characterized as a modified intention to treat
approach because the analysis population for the test
will be all randomized pregnancies for which the delivery
occurs after 20 weeks. Earlier deliveries (miscarriages)
will be considered missing completely at random for
purposes of this analysis.
In order to evaluate the sensitivity of the primary hy-
pothesis test to the assumption by which early deliveries
or losses are treated as randomly missing and to control
for potential confounders of the treatment effect, add-
itional analyses will be conducted using a series of three
generalized linear models. These generalized linear models
will be fit with the binary outcome of preterm (<37 week
delivery) as the outcome measure. The initial model will
include terms for treatment, site, and a treatment by site
interaction. If the treatment by site interaction term is
found to be significant (p < 0.05), then all subsequent
models will include the interaction term and all effects will
be reported by site. If the interaction term is not signifi-
cant, it will be removed from the model and this initial
model be used to estimate an unadjusted treatment effect
controlling for site. The second series of models will in-
clude any demographic or clinical variable found to differ
significantly between the treatment arms in the prelimin-
ary analyses described above. These models will be used
to generate adjusted estimates of the treatment effect con-
trolling for potential confounders. The third set of models
will utilize extensions of the generalized linear model that
incorporate inverse probability weighting to evaluate the
sensitivity of the inference to treatment of miscarriages as
randomly missing [41].
Secondary and exploratory analysis
This study has been designed to evaluate formally the dif-
ferences between the two treatment arms for three second-
ary outcomes: the risk of perinatal mortality; the risk of
eclampsia/preeclampsia, and the risk of a SGA infant. As
with the primary analyses, each of these outcomes will be
examined individually using formal tests of hypotheses that
the risk differs between the two arms based on CMH tests
stratified by Global Network sites. Analyses for each of
these 3 secondary outcomes will utilize the same modified
intention-to-treat population used for the primary out-
come. Each of these hypothesis tests will be conducted at
the 0.05 level of significance with no adjustment for mul-
tiple comparisons. In addition to this set of formal hypoth-
esis tests, model based analyses comparable to those
conducted for the primary analyses will be used to evaluate
potential heterogeneity of treatment effect across sites and
evaluate potential confounding. For each of the outcomes,
an initial model will include terms for treatment, site, and a
treatment by site interaction. If the treatment by site inter-
action term is found to be significant (p < 0.05), then all
subsequent models will include the interaction term and all
effects will be reported by site. If the interaction term is not
significant, it will be removed from the model and this ini-
tial model be used to estimate an unadjusted treatment
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effect controlling for site. The second series of models will
include any demographic or clinical variable found to differ
significantly between the treatment arms in the preliminary
analyses described above. These models will be used to gen-
erate adjusted estimates of the treatment effect controlling
for potential confounders.
In addition to these planned formal secondary out-
come analyses, we will also conduct exploratory out-
comes for a number of other binary outcomes. The
analytic approach for these exploratory analyses, will be
comparable to the approach described above for the pri-
mary and formal secondary analyses. However, these ex-
ploratory analyses will focus on estimation of effect sizes
and generation of hypotheses rather than on formal hy-
pothesis tests. Initially, contingency tables will be used
to generate estimates of the risk of each outcome for the
two treatment arms, both overall and separately by Glo-
bal Network (GN) site; these contingency tables will also
be used to generate estimates of the relative risk associ-
ated with treatment by site and aggregated across sites
adjusting for site. For each outcome a series of general-
ized linear models analogous to those described for the
primary outcome will be fit to generate unadjusted esti-
mates of risk, estimates of risk adjusted for potential
confounders, and estimates of risk adjusted to account
for any possible differences in risk between the arms as-
sociated with miscarriages.
Sample size and power estimates
The risk of preterm birth < 37 weeks gestation in un-
treated nulliparous women was estimated to be about
8.0% for the EAGeR trial [15, 42]. Unpublished data for
2012 from the Global Network sites show preterm birth
rates among sites, ranging from 2.9% to 9.8%, while
WHO estimates the range for the countries in which
Global Network sites are located to be 7.7% to 16.7% [2].
In developing sample size estimates we considered risks
in the range of 8% to 14% and ultimately selected sample
sizes based on a conservative estimate of 8%. Because
the association of LDA and preterm birth may differ in
international settings, we examined sample size require-
ments for reductions of 40%, 25%, and 20%. As shown
in Table 3, the number of evaluable participants needed
to detect a 20% reduction from a usual rate of 8% pre-
term births with 90% power is 5,483 per treatment arm.
A conservative estimate of effect size was selected that
would still be clinically relevant. To account for the loss
of evaluable subjects due to spontaneous abortion, which
are anticipated to occur in approximately 5% of partici-
pants) and loss to follow-up (assumed to be in the 1% to
2% range), sample sizes were increased by 8% to obtain a
final sample size of 11,920 (or 5,960 per treatment arm).
Sample size—secondary outcomes
One of the key secondary objectives of this trial is to
evaluate the effect of low dose aspirin on perinatal mor-
tality. We evaluated the reduction in perinatal mortality
that could be detected with 80% power and 90% power
under the assumption that the sample size for the study
would be based on that needed to achieve the primary
aim of demonstrating a 20% reduction in low-birth
weight infants. The analyses were based on the assump-
tion that the perinatal mortality rate in the Global Net-
work population is approximately 45 perinatal deaths
per 1000 deliveries [40]. With this estimated underlying
mortality rate and 5,483 evaluable subjects per treatment
arm required to demonstrate the 20% reduction in low
birth weight prevalence as outlined in the primary aim,
the study will have 80% power to detect a 24% reduction
in perinatal mortality and 90% power to detect a 27% re-
duction in perinatal mortality.
To determine the sample size actually needed to dem-
onstrate the reduction in perinatal mortality expected if
the intervention results in a 20% reduction in prevalence
of low birth weight infants, we examined both the preva-
lence of low birth weight infants across the Global
Table 3 Evaluable sample size estimates
PTB rate in
Placebo Arm
PTB rate
in ASA
% Red. Sample size
per group
PTB rate
in ASA
% Red. Sample size
per group
PTB rate
in ASA
% Red. Sample size
per group
Power = 80% (α = 0.05; β = 0.2)
8% 4.8% 40% 918 6.0% 25% 2554 6.40% 20% 4096
10% 6.0% 40% 721 7.5% 25% 2005 8.00% 20% 3213
12% 7.2% 40% 591 9.0% 25% 1638 9.60% 20% 2625
14% 8.4% 40% 497 10.0% 25% 1377 11.20% 20% 2204
Power = 90% (α = 0.05; β = 0.1)
8% 4.8% 40% 1228 6.0% 25% 3419 6.40% 20% 5483
10% 6.0% 40% 965 7.5% 25% 2683 8.00% 20% 4301
12% 7.2% 40% 790 9.0% 25% 2193 9.60% 20% 3513
14% 8.4% 40% 665 10.5% 25% 1842 11.20% 20% 2950
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Network sites and the perinatal mortality risk in both
the low birth weight and normal birth weight infants.
Based on 2013 MNH Registry data, the prevalence of
low birth weight among all Global Network deliveries
was 16.3% and the perinatal mortality rates were 20.5
per 1000 deliveries among normal birth weight infants
and 162.3 per 1000 deliveries among low birth weight
infants; these values yield a weighted average perinatal
mortality rate of 43.6 per 1000 deliveries. If the LDA
intervention is effective in reducing the prevalence of
low birth weight deliveries by 20% (i.e. reducing the
prevalence from 16.3% to 13%) and the conditional risk
of perinatal mortality is unchanged in the low birth
weight and normal birth weight cohorts, we would ex-
pect the resultant overall perinatal mortality rate to be
reduced to 38.9 per 1000 deliveries or a 10.8% reduction.
Detection of a reduction of this magnitude with 80%
power would require an evaluable sample size of greater
than 28,000 evaluable deliveries per treatment arm, and
the study would need over 37,000 evaluable deliveries
per arm to achieve 90% power to detect a reduction of
this level in perinatal mortality.
Given the sample sizes associated with the second ap-
proach, the best alternative appears to be to power the
study to demonstrate the 20% reduction in prevalence of
low birth weight deliveries with a commitment to generate
point and interval estimates of the impact of the interven-
tion on perinatal mortality. By examining the risk of peri-
natal mortality in both the normal and low birth weight
infants in the two arms, the trial would provide some
insight about impacts of the intervention on mortality other
than that mediated through the effect on birth weight.
We also conducted power analyses to examine the ef-
fect sizes that could be detected with the planned sam-
ple sizes for two additional secondary outcomes,
prevalence of SGA infants and incidence of eclampsia/
preeclampsia in the target population. Preliminary infor-
mation from the 2013 Global Network MNH Registry
indicates that the risk of each of these events in the
population of interest is approximately 5%. Under the
assumption of 5,483 evaluable participants in each treat-
ment arm and an assumed Type I error rate of 0.05 for
per-comparison analyses (i.e. no control for multiple com-
parisons in the analyses of these secondary outcomes), the
study will have 70% power to detect a 20% reduction in
the risk of each of these outcome measures, 85% power to
detect a 24% reduction and 90% power to detect a 26% re-
duction. Consequently, the study is reasonably powered to
examine these secondary outcome measures.
Available population
The sites of the Global Network have access to approxi-
mately 68,000 deliveries annually with 24,000 being po-
tentially eligible pregnancies for this study. Previous
studies of interventions during pregnancy have experi-
enced high rates of enrollment in this population. The
Global Network sites estimate that between one third
and one half of eligible women will enroll in this proto-
col, which will allow the study to meet recruitment goals
within 18-24 months.
Projected recruitment time
Each site will begin recruitment after their site-specific
regulatory approvals are in place, the site has been ad-
equately prepared, and training is completed. This will
require a staggered start, as the timeline for these activ-
ities will vary per site. The projected timeline for this
study is approximately 3 years. This includes a 12 month
preparatory phase with 3 months for training, an
18 month recruitment period, and 6 months for data
cleaning and analysis (Table 4).
Study monitoring plan
Serious adverse events
Serious Adverse events (SAEs) will be monitored con-
tinuously using a special form that will be required for
any event that meets the following criteria:
 Results in death;
 Is life-threatening;
Table 4 Study timeline
YR 1 YR 2 YR 3 YR 4
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2
Preparatory Activities
Document Development (Protocol, forms, etc.) ● ● ● ●
Procurement of medication and other materials ● ● ● ●
Approvals (IRB, ERC, Drug Authorities, etc.) ● ● ● ●
Site Preparation ● ● ● ●
Training ● ● ●
Recruitment (24 months) ● ● ● ● ● ● ● ●
Data Cleaning and Analysis (6 months) ● ●
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 Requires hospitalization or prolongs existing
hospitalization;
 Results in persistent or significant disability or
incapacity;
 Any other serious or unexpected adverse event that
the study investigator(s) feels should be reported.
The specific adverse events to be monitored in this trial
include maternal death, GI bleeding (vomiting blood),
fetal anomaly, gastroschisis, post-partum hemorrhage, or
antepartum hemorrhage.
Data monitoring plan and stopping rules
All Global Network sites will report data to the Global
Network Data Coordinating Center (DCC) (RTI Inter-
national). Data will be used to evaluate protocol adherence
and site performance (e.g., recruitment, loss to follow-up,
data quality). The DCC will provide standardized progress
reports to NICHD and site investigators on a monthly
basis to monitor outcome variables and adverse events.
Oversight of the trial will be handled by two principal
groups with different focuses:
1. Protocol-focused Steering Committee (SC): The SC
is comprised of the Central Study Team from
Christiana Care and Jawaharlal Nehru Medical
College (JNMC), NICHD, the DCC, and
investigators from each of the participating sites (see
Table 5). The Central Study Team, with assistance
from NICHD and the DCC, will have primary
responsibility for overall study design, development
of study materials and procedures, and oversight of
study implementation. They will meet via conference
call bi-weekly to monitor study progress and
ensure proper implementation of the trial. The
site Investigators will be responsible for providing
guidance on study design, developing site-specific
implementation plans, ensuring study staff are properly
trained, and providing oversight of the study at the site
level. The SC will convene via conference call at least
once per quarter and will meet in person twice a year
to discuss study design and implementation issues.
Members of the Central Study team, NICHD, and RTI
will also conduct site visits, as the budget allows, to
bolster enthusiasm, provide hands-on training and
education to the participating staff, and address site-
specific issues, if any.
2. Data Monitoring Committee (DMC): The DMC, a
standing group that monitors all NICHD-funded
Global Network studies, will be responsible for
ensuring safe and ethical treatment of study
participants through monitoring of the study. The
membership will include, at a minimum, a
statistician, obstetrician, pediatrician and an expert
in international health. The DMC designated by
NICHD will review the data collected at approximate
6 month intervals throughout the course of the study.
The DMC reports, which are prepared by the Data
coordinating center, will include information on study
enrollment rates and participant progress through the
study, participant compliance with protocol-specified
treatment regimens, protocol violations, adverse
events, and efficacy outcomes. The focus of the DMC
review will be on monitoring participant safety and
study progress/futility but data on treatment
effectiveness will also be presented to frame the
DMC discussions on safety and futility. However,
no formal interim analysis of efficacy or effectiveness
are planned and the DMC will not be responsible for
stopping the trial for efficacy. The DMC will be charged
with monitoring adverse events and side effects from
LDA. All known associated side effects and specific
obstetric or fetal concerns will be considered reportable
to the DMC. The study will be reviewed by the DMC
bi-annually at a minimum, but may be reviewed more
frequently if concerns are raised about participant
safety or about adequate process of the study.
Data management procedures
Data will be collected both prospectively and from existing
clinical records, using hard copy forms or Android Tablets.
Regardless of data capture methodology, all data will be
kept confidential. Each participant will be assigned a unique
study ID which will be used to identify the participant. Only
the screening log will contain the name (which is not trans-
mitted). When hard copy forms are used, they will be
retained in a secure location for possible editing or queries
at the central data entry site. Data will be entered into com-
puters using the Data Management System (DMS) devel-
oped by RTI and the assigned study number. The DMS will
also allow site staff to produce project reports and backup
the study database. Electronic data will be transferred from
each data management computer to a single Research Unit
Data Center (RUDC) in each country, creating a complete
data repository. At least once per week, data will be trans-
mitted from the RUDC to the DCC. The data center will
conduct training on the DMS system, as needed, and will
maintain the central database for the study.
Precision and accuracy of actual data collected will be
assessed by chart review (random 5%) and internal pro-
cedures using the computer program. Monthly audits
and incomplete data reports will be performed by a re-
view team consisting of at least of the SFI and the coun-
try coordinator. Data editing and error resolution will be
performed monthly. In addition, a sample of participants
will be visited to confirm their participation, with proce-
dures determined per site. These activities will be shared
between the site and the data center.
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Table 5 ASPIRIN Study Team Members
Central Study Team: Global Network
Site 08 (Belgaum, India)
Richard Derman, MD, MPH Principal Investigator, Thomas Jefferson University,
Philadelphia, PA USA
Bhalchandra Kodkany, MD, MBBS Senior Foreign Investigator, KLE
University’s JN Medical College, Belagavi, India
Shivaprasad S. Goudar MD, MHPE Co-Investigator, KLE University’s JN
Medical College, Belagavi, India
Matthew K. Hoffman, MD, MPH Lead Investigator for ASPIRIN Protocol,
Christiana Care, Newark, DE USA
Mrityunjay C. Metgud, MD ASPIRIN Country Coordinator, KLE University’s
JN Medical College, Belagavi, India
Frances Jaeger, MA, DrPhCo-Investigator, Thomas Jefferson University,
Philadelphia, PA USA
Amit Revankar Data Manager, KLE University’s JN Medical College,
Belagavi, India
Data Coordinating Center - RTI International
Elizabeth McClure, PhD Principal Investigator Data Coordinating Center,
RTI International, Research Triangle Park, NC USA
Dennis Wallace, PhD
Senior Statistician, RTI International, Research Triangle Park, NC USA
Norman Goco, MHS
Protocol Manager, RTI International, Research Triangle Park, NC USA
Jay Hemingway-Foday, MPH, MSW Protocol Manager for ASPIRIN Protocol,
RTI International, Research Triangle Park, NC USA
Steve Litavecz, MBA
Data Manager, RTI International, Research Triangle Park, NC USA
Janet Moore, MS Statistician, RTI International, Research Triangle Park, NC USA
Emily MacGuire, MPH
Study Coordinator, RTI International, Research Triangle Park, NC USA
Eunice Kennedy Shriver National Institute of Child Health and Human
Development (NICHD)
Marion Koso-Thomas, MD MPH, Medical Officer, Global Network for Women's
and Children's Health Research, NICHD, Washington, DC USA
Menachem Miodovnik, MD
Medical Officer, Global Network for Women’s and Children’s Health
Eunice Kennedy Shriver National Institute of Child Health and Human
Development (NICHD)
Site Investigators
Global Network Site 02 (Democratic Republic of Congo)
Carl L. Bose, M.D.
Principal Investigator, University of North Carolina School of Medicine
Antoinette Tshefu, M.D, Ph.D., M.P.H
Senior Foreign Investigator, Kinshasa School of Public Health, Kinshasa,
Democratic Republic of Congo
Adrien Lokangaka, M.D., M.P.H.
Country Coordinator, Kinshasa School of Public Health, Kinshasa,
Democratic Republic of Congo
Daniel Ishoso, MD ASPIRIN Coordinator, Kinshasa School of Public
Health, Kinshasa, Democratic Republic of Congo
Global Network Site 06 (Guatemala)
Nancy Krebs, MD
Principal Investigator, University of Colorado Health Care System (UCHCS)
K. Michael Hambidge, MD
Co-Investigator, University of Colorado Health Care System (UCHCS)
Ana Garces, MD, MPH
Senior Foreign Investigator, Instituto de Nutrición de Centroamérica y
Panamá (INCAP), Guatemala City, Guatemala
Table 5 ASPIRIN Study Team Members (Continued)
Lester Figueroa, MD
Country Coordinator, Instituto de Nutrición de Centroamérica y Panamá
(INCAP), Guatemala City, Guatemala
Maynor Manrique,
Data Manager, INCAP, Instituto de Nutrición de Centroamérica y Panamá
(INCAP), Guatemala City, Guatemala
Global Network Site 09 (Pakistan)
Robert L. Goldenberg, MD
Principal Investigator, Columbia University
Sarah Saleem, MD
Senior Foreign Investigator, Aga Khan University, Karachi, Pakistan
Saleem Jessani
ASPIRIN Coordinator, Aga Khan University Karachi, Pakistan
Zaheer Habib
Data Manager, Aga Khan University, Karachi, Pakistan
Global Network Site 11 (Nagpur, India)
Patricia L. Hibberd, MD, PhD
Boston University School of Public Health
Archana Patel, MD, DNB, MSCE
Senior Foreign Investigator, Lata Medical Research Foundation (LMRF),
Nagpur, India
Prabir B. Das, MD
ASPIRIN Country Coordinator, Lata Medical Research Foundation (LMRF),
Nagpur, India
Amber Prakash,
Data Manager, Lata Medical Research Foundation (LMRF), Nagpur, India
Global Network Site 03 (Zambia)
Wally Carlo, MD
Principal Investigator, University of Alabama at Birmingham
Elwyn Chomba, MBChB, DCH, MRCP
Senior Foreign Investigator, University Teaching Hospital, Lusaka, Zambia
Musaku Mwenechanya, MD
Country Coordinator, University Teaching Hospital, Lusaka, Zambia
Cindy Chirwa
ASPIRIN Coordinator, University Teaching Hospital, Lusaka, Zambia
Ernest Banda
Data Manager, University Teaching Hospital, Lusaka, Zambia
Global Network Site 12 (Kenya)
Edward A. Liechty, MD
Principal Investigator, Indiana University School of Medicine
Fabian Esamai, MBChB, MMed, PhD
Senior Foreign Investigator, Moi University School of Medicine, Eldoret,
Kenya
Emmah Achieng
ASPIRIN Coordinator, Moi University, Eldoret, Kenya
Kevin Otieno
Data Manager, Moi University, Eldoret, Kenya
Technical Advisory Group
Robert M. Silver, MD
University of Utah Health Sciences Center
Enrique Schisterman, Ph.D
Chief and Senior Investigator
Epidemiology Branch, DIPHR
Eunice Kennedy Shriver National Institute of Child Health and Human
Development
Rob Nathan, MD
Ultrasound Quality Control Advisory,
Department of Radiology, University of Washington, Seattle, WA
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Quality control
Training
All study personnel must participate in training on the
proper implementation of study procedures and the ethics
of conducting research with human subjects before begin-
ning any research activity. The SFI and project coordinator
will ensure that all study personnel receive appropriate
training, and obtain required certification ensuring that they
have met training objectives. RTI will be responsible for de-
veloping a certification test. The SFI and project manager
will be responsible for overseeing the certification process.
Study monitoring
Major monitoring responsibilities of the PI/SFI, assisted
by the country coordinator, are (1) confirming proper IRB
approval; (2) monitoring the delivery of the study inter-
vention; (3) assessing and evaluating the quality of study
implementation; (4) ensuring compliance with the inter-
vention, including proper randomization; (5) evaluating
accuracy, precision, and completeness of data collected,
entered, and transmitted (along with the DCC); (6) ensur-
ing that all personnel are fulfilling their obligations; (7)
maintaining morale and enthusiasm of the staff; (8) hand-
ling ad hoc problems and maintaining communication; (9)
ensuring inter-site consistency; and (10) proposing im-
provements to the monitoring activities.
NICHD and the DCC staff will conduct site visits as
needed. These visits will include review of individual par-
ticipant records, including supporting data, to ensure pro-
tection of study participants, compliance with the protocol,
and accuracy and completeness of records. The SFI/PI will
make study documents (e.g., logbooks, data forms, staff
training certificates) and pertinent hospital/clinic records
readily available for inspection by the local IRB, site moni-
tors, and the NICHD for confirmation of the study data.
Drug quality assurance and monitoring
The study drug manufacturer will have a Good Manu-
facturing Practices (GMP) designation vetted by the
FDA and a certificate of authenticity will be provided.
Each site will adapt best practice guidelines for drug
shipment and storage to the needs and infrastructure of
their local environment. Study staff will be trained in on
the drug shipment and storage plan to ensure that best
practices are maintained at all time. Additionally, partici-
pants will receive detailed instruction on proper storage
of the study drug at home. Drug stability information
will be maintained throughout the study. For quality as-
surance, a sample of pills from each site will be ran-
domly selected and tested for bioavailability at multiple
time points during the study period. A sample from each
batch will be tested.
Ultrasound gestational age dating
All study sonographers will be certified to assess gestational
age using CRL measurements. A sample of ultrasound im-
ages at each site will be reviewed by study investigators to
ensure that CRL is accurately measured and gestational age
is accurately assigned. If discrepancies are found, the sono-
graphers will be retrained. Ultrasound will be used only for
pregnancy dating and no other purpose.
Discussion
This study will assess the impact of initiation of LDA be-
tween 6 and 14 weeks of gestation. Though several large
studies have examined the effects of aspirin on pregnancy,
this study is unique because it will examine this treatment
early in pregnancy in low-middle income countries with
preterm birth as a primary outcome. Though studies of
LDA initiated later in pregnancy [31] have consistently
shown benefit, the extant of impact may be muted by the
fact that late initiation may fail to protect the placenta as
it undergoes cellular division and invests itself into the
maternal decidua. Secondary analyses have consistently
suggested that the effect size is markedly increased when
LDA is initiated prior to 16 weeks; however, this will be
the first study to examine this question on this scale. The
importance of developing low-cost, high impact interven-
tions in low-middle income countries is magnified as they
are often unable to bear the financial costs of treating ill-
ness. Likewise this approach examines the important
question of whether the biologic underpinning diseases
are similar between the developed and developing world.
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